trending Market Intelligence /marketintelligence/en/news-insights/trending/cootukzlextx-dxmrub_5a2 content esgSubNav
In This List

Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Sage Therapeutics, Shionogi to collaborate on depressive disorder treatment

Sage Therapeutics Inc. and Shionogi & Co. Ltd. entered a collaboration to develop and sell its experimental drug Sage-217 for treating major depressive disorder and other indications.

Under the deal, Osaka, Japan-based Shionogi will shoulder clinical development, regulatory filings and commercialization of Sage-217 in Japan, Taiwan and South Korea.

Shionogi will pay Cambridge, Mass.-based Sage $90 million up front. The latter will also be eligible to receive up to $485 million in milestone payments as well as tiered royalties on sales of Sage-217.

Further, Shionogi granted Sage certain rights to co-promote Sage-217 in Japan in all indications, while Sage maintains the exclusive rights to develop and sell Sage-217 outside of Japan, Taiwan and South Korea.

In February, Sage-217 was granted breakthrough therapy designation by the U.S. Food and Drug Administration based on data from a phase 2 study.